We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00747279
Recruitment Status : Unknown
Verified September 2008 by Hospital Sao Domingos.
Recruitment status was:  Recruiting
First Posted : September 5, 2008
Last Update Posted : September 9, 2008
Information provided by:

September 4, 2008
September 5, 2008
September 9, 2008
June 2007
Not Provided
Neurological outcome through the Glasgow Outcome Scale Extended [ Time Frame: At least 4 months after hospital discharge ]
Same as current
Complete list of historical versions of study NCT00747279 on ClinicalTrials.gov Archive Site
  • NIHSS during ICU stay [ Time Frame: ICU stay ]
  • Hospital mortality [ Time Frame: Hospital stay ]
Same as current
Not Provided
Not Provided
Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke
Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke
The purpose of this prospective randomized controlled trial was to compare intensive insulin therapy with a carbohydrate restrictive strategy in patients with acute ischemic stroke evaluating the outcome through the Glasgow Outcome Scale Extended, hospital mortality and NIHSS during the ICU stay.
Not Provided
Phase 4
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Acute Ischemic Stroke
  • Other: Carbohydrate restrictive strategy
    Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
  • Drug: Intensive insulin therapy
    Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
  • Experimental: 1
    Carbohydrate restrictive strategy
    Intervention: Other: Carbohydrate restrictive strategy
  • Active Comparator: 2
    Intensive insulin therapy
    Intervention: Drug: Intensive insulin therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
Not Provided
Not Provided

Inclusion Criteria:

  • Adult patients with acute ischemic stroke defined as: Abrupt onset of focal neurologic deficit
  • No evidence of intracranial hemorrhage at non-contrasted CT scan.

Exclusion Criteria:

  • Age below 18
  • Pregnancy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Hospital Sao Domingos
Not Provided
Not Provided
Hospital Sao Domingos
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP